Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence ...

The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

A take-at-home tablet for multiple sclerosis (MS) is set to be more broadly rolled out on the NHS, potentially benefiting ...

The Scottish Medicines Consortium is reviewing cladribine for broader use in relapsing forms of the condition.

The National Institute for Health and Care Excellence (NICE) has recommended cladribine (Mavenclad, Merck Serono) for adults in England with relapsing-remitting multiple sclerosis (RRMS).

Just days after announcing sweeping job cuts at NHS England, UK Prime Minister Keir Starmer has said that the government ...

Find insight on Merck KGaA, Bayer, Jazz Pharmaceuticals and the use of AI in China’s healthcare sector in the latest Market ...

The Merck KGaA collaborated with actress and patient advocate Selma Blair for the I’m Ready campaign. When EMD Serono embarked on a campaign to empower patients living with relapsing multiple ...

No cruel intentions here: Merck KGaA’s U.S. pharma arm has recruited actor Selma Blair for a collaboration around multiple sclerosis treatment Mavenclad. Blair, best known for her roles in turn ...

Thousands of NHS patients in England with multiple sclerosis (MS) are set to benefit from a life-changing ‘take at home’ tablet, as the NHS becomes the first healthcare system in Europe to roll it out ...

The health service is thought to be the first in Europe to widely rollout cladribine, also known as Mavenclad and made by Merck. It has been approved by the National Institute for Health and Care ...